Home » Stocks » KIN

Kindred Biosciences, Inc. (KIN)

Stock Price: $3.85 USD -0.04 (-1.03%)
Updated December 1, 4:00 PM EST - Market closed
After-hours: $3.81 -0.04 (-1.04%) Dec 1, 6:41 PM

Stock Price Chart

Key Info

Market Cap 151.88M
Revenue (ttm) 42.61M
Net Income (ttm) -26.63M
Shares Out 39.45M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $3.85
Previous Close $3.89
Change ($) -0.04
Change (%) -1.03%
Day's Open 3.89
Day's Range 3.80 - 3.95
Day's Volume 203,871
52-Week Range 3.26 - 11.01

More Stats

Market Cap 151.88M
Enterprise Value 113.02M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 39.45M
Float n/a
EPS (basic) -0.69
EPS (diluted) -0.68
FCF / Share -0.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 678,224
Short Ratio 3.49
Short % of Float n/a
Beta 1.24
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.56
PB Ratio 2.01
Revenue 42.61M
Operating Income -25.10M
Net Income -26.63M
Free Cash Flow -21.10M
Net Cash 38.86M
Net Cash / Share 0.98
Gross Margin 93.74%
Operating Margin -58.91%
Profit Margin -62.50%
FCF Margin -49.50%
ROA -32.39%
ROE -31.01%
ROIC -25.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(202.34% upside)
Current: $3.85
Target: 11.64
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth116.48%-------
Gross Profit3.671.64------
Operating Income-62.57-51.26-31.65-22.82-27.26-27.23-4.22-0.12
Net Income-61.39-49.69-30.88-22.50-27.13-27.14-4.21-0.12
Shares Outstanding38.6631.0025.0819.8719.7718.783.732.11
Earnings Per Share-1.59-1.60-1.23-1.13-1.37-1.44-1.13-0.06
Operating Cash Flow-56.34-45.04-21.88-18.78-22.76-21.93-1.57-0.06
Capital Expenditures-8.42-13.67-5.92-0.95-0.73-0.44-0.02-
Free Cash Flow-64.77-58.71-27.80-19.73-23.49-22.37-1.59-0.06
Cash & Equivalents71.7173.9381.0256.7673.0410165.330.94
Total Debt22.52-------
Net Cash / Debt49.1973.9381.0256.7673.0410165.330.94
Book Value81.9291.2184.6857.6876.3799.0263.28-0.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kindred Biosciences, Inc.
Country United States
Employees 156
CEO Richard H. Chin

Stock Information

Ticker Symbol KIN
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: KIN
IPO Date December 12, 2013


Kindred Biosciences, a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.